RCKT - ROCKET PHARMACEUTICALS, INC.

QQQ $ 441.71 $ 1.04 (0.24 %)

DIA $ 395.04 $ 1.18 (0.3 %)

SPY $ 520.76 $ 0.67 (0.13 %)

TLT $ 90.14 $ -0.51 (-0.56 %)

GLD $ 218.73 $ 1.76 (0.81 %)

Previous Close

$ 22.72

Open

$ 23.29

Bid

$ 0.00 x 0

Ask

$ 0.00 x 0

Day's Range

$ 22.74 - $ 23.63

52 Week Range

$ 14.89 - $ 32.53

Volume

401,938

Average Volume

Market Cap

2.13B

Beta (5Y Monthly)

$ 1.27

PE Ratio (TTM)

EPS (TTM)

TBD

Earnings Date

Dividend & Yield

na ($ 0.00)

Last Ex-Dividend

1y Target Est

TBD na

How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In

#	Filing Date	Period End Date	Type
1	05-07-2024	03-31-2024	10-Q
2	02-27-2024	12-31-2023	10-K
3	11-07-2023	09-30-2023	10-Q
4	08-09-2023	06-30-2023	10-Q
5	05-05-2023	03-31-2023	10-Q
6	02-28-2023	12-31-2022	10-K
7	11-04-2022	09-30-2022	10-Q
8	08-09-2022	06-30-2022	10-Q
9	05-06-2022	03-31-2022	10-Q
10	02-28-2022	12-31-2021	10-K
11	11-05-2021	09-30-2021	10-Q
12	08-09-2021	06-30-2021	10-Q
13	05-10-2021	03-31-2021	10-Q
14	03-01-2021	12-31-2020	10-K
15	11-06-2020	09-30-2020	10-Q
16	08-05-2020	06-30-2020	10-Q
17	05-08-2020	03-31-2020	10-Q
18	03-06-2020	12-31-2019	10-K
19	11-08-2019	09-30-2019	10-Q
20	08-08-2019	06-30-2019	10-Q
21	05-09-2019	03-31-2019	10-Q
22	03-08-2019	12-31-2018	10-K
23	11-09-2018	09-30-2018	10-Q
24	08-14-2018	06-30-2018	10-Q
25	05-11-2018	03-31-2018	10-Q
26	03-07-2018	12-31-2017	10-K
27	11-08-2017	09-30-2017	10-Q
28	08-03-2017	06-30-2017	10-Q
29	05-10-2017	03-31-2017	10-Q
30	03-16-2017	12-31-2016	10-K
31	11-09-2016	09-30-2016	10-Q
32	08-10-2016	06-30-2016	10-Q
33	05-11-2016	03-31-2016	10-Q
34	03-23-2016	12-31-2015	10-K
35	11-12-2015	09-30-2015	10-Q
36	08-07-2015	06-30-2015	10-Q
37	05-14-2015	03-31-2015	10-Q
38	03-31-2015	12-31-2014	10-K

Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In

#	Date	Analyst Firm	Upside/Downside	Price Target Change	Rating Change	Current Rating

News
OPINIONS

News

OPINIONS

Rocket Pharmaceuticals Presents Longer-Ter...
05/10/2024 10:04:07

Long-term KRESLADI follow-up data demonstrate survival of 100% in the absence of allogeneic hematopoietic stem cell transplanta...

Needham Reiterates Buy on Rocket Pharmaceu...
05/07/2024 11:17:18

Needham analyst Gil Blum reiterates Rocket Pharmaceuticals (NASDAQ:RCKT) with a Buy and maintains $53 price target.

Rocket Pharmaceuticals Q1 EPS $(0.66) Beat...
05/06/2024 20:03:12

Rocket Pharmaceuticals (NASDAQ:RCKT) reported quarterly losses of $(0.66) per share which beat the analyst consensus estimate o...

Needham Reiterates Buy on Rocket Pharmaceu...
04/10/2024 10:08:21

Needham analyst Gil Blum reiterates Rocket Pharmaceuticals (NASDAQ:RCKT) with a Buy and maintains $53 price target.

Goldman Sachs Initiates Coverage On Rocket...
04/02/2024 11:07:21

Goldman Sachs analyst Richard Law initiates coverage on Rocket Pharmaceuticals (NASDAQ:RCKT) with a Neutral rating and annou...

The European Medicines Agency Accepted The...
04/02/2024 10:04:04

Rocket Pharmaceuticals Announces Appointme...
03/26/2024 20:14:28

Aaron Ondrey joins as Chief Financial Officer bringing seasoned leadership experience in financial management, strategic planni...

UBS Maintains Buy on Rocket Pharmaceutical...
03/01/2024 16:53:25

UBS analyst Colin Bristow maintains Rocket Pharmaceuticals (NASDAQ:RCKT) with a Buy and lowers the price target from $56 to ...

JP Morgan Maintains Overweight on Rocket P...
02/27/2024 18:25:15

JP Morgan analyst Eric Joseph maintains Rocket Pharmaceuticals (NASDAQ:RCKT) with a Overweight and lowers the price target f...

Cantor Fitzgerald Maintains Overweight on ...
02/27/2024 14:31:25

Cantor Fitzgerald analyst Josh Schimmer maintains Rocket Pharmaceuticals (NASDAQ:RCKT) with a Overweight and maintains $65 p...

Rocket Pharmaceuticals Q4 EPS $(0.64) Beat...
02/26/2024 21:07:00

Rocket Pharmaceuticals (NASDAQ:RCKT) reported quarterly losses of $(0.64) per share which beat the analyst consensus estimate o...

Needham Reiterates Buy on Rocket Pharmaceu...
02/13/2024 16:46:56

Needham analyst Gil Blum reiterates Rocket Pharmaceuticals (NASDAQ:RCKT) with a Buy and maintains $53 price target.

Rocket Pharmaceuticals Announced The FDA H...
02/13/2024 12:27:29

The FDA extended the review period by three months, to June 30, 2024, to allow additional time to review clarifying Chemistry, ...

Cantor Fitzgerald Reiterates Overweight on...
01/31/2024 17:54:35

Cantor Fitzgerald analyst Louise Chen reiterates Rocket Pharmaceuticals (NASDAQ:RCKT) with a Overweight and maintains $65 pr...

merit-medical-systems-and-other-big-stocks-moving-lower-in-tuesdays-pre-market-session

Merit Medical Systems And Other Big Stocks...
12/05/2023 10:21:44

U.S. stock futures traded lower this morning, with the Dow Jones futures falling more than 40 points on Monday.

Analyst Ratings for Rocket Pharmaceuticals
11/07/2023 16:00:11

Needham Reiterates Buy on Rocket Pharmaceu...
11/07/2023 15:42:02

Needham analyst Gil Blum reiterates Rocket Pharmaceuticals (NASDAQ:RCKT) with a Buy and maintains $53 price target.

Rocket Pharmaceuticals Cash Equivalents An...
11/06/2023 21:16:46

Rocket Pharmaceuticals Q3 EPS $(0.75) Beat...
11/06/2023 21:11:30

Rocket Pharmaceuticals (NASDAQ:RCKT) reported quarterly losses of $(0.75) per share which beat the analyst consensus estimate o...

Benzinga's Top Ratings Upgrades, Downgrade...
10/24/2023 15:00:43